| Literature DB >> 26543488 |
Cai-Yu-Zhu Wen1, Ya-Fei Liu2, Li Zhou3, Hong-Xing Zhang3, Sheng-Hao Tu4.
Abstract
Acupuncture point application therapies, including San-Fu-Tie and San-Fu-Jiu, have been widely employed to treat diseases with attacks in winter during dog days in China. The therapies combine Chinese herbal medicine and acupuncture points with the nature. However, the previous studies were reported to be unsystematic and incomplete. To develop a more comprehensive understanding of the effects of acupuncture point application therapies on allergic rhinitis and asthma, a systematic review of the literature up to 2015 was conducted. After filtering, eighteen randomized controlled trials (RCTs) involving 1,785 subjects were included. This systematic and narrative review shows that acupuncture point application therapies have been extensively applied in the treatment of allergic rhinitis and asthma with advantages of favorable treatment effect, convenient operation, receiving patients' good acceptability and compliance, and few side effects. Meanwhile, the study elaborated the operating process of San-Fu-Tie and San-Fu-Jiu in detail. The review may provide a reference for clinical application in future. However, the efficacy, safety, and mechanisms of San-Fu-Tie and San-Fu-Jiu in treating the above diseases need to be validated by more well-designed and fully powered RCTs in a larger population of patients.Entities:
Year: 2015 PMID: 26543488 PMCID: PMC4620249 DOI: 10.1155/2015/846851
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Chinese herb medicine pastes for San-Fu-Tie.
Figure 2San-Fu-Tie was applied on Shenshu (BL23), Yaoyangguan (GV3), Mingmen (GV4), and Pishu (BL20).
Figure 3San-Fu-Tie was applied on Dazhui (GV14), Fengmen (BL12), and Feishu (BL13).
Figure 4The left scar after San-Fu-Tie or San-Fu-Jiu.
Figure 5Moxa cones for San-Fu-Jiu.
Figure 6San-Fu-Jiu was being applied.
AR and acupuncture point application therapies.
| Author | Number and range of age | Intervention (herbal medicine and acupoints) and duration | Outcomes | Adverse events | Jadad score | ||
|---|---|---|---|---|---|---|---|
| Experimental | Control | Experimental | Control | ||||
| Zhu 2010 [ | 47/5–55 | 44/8–50 | San-Fu-Tie, for one year | Cetirizine and beclometasone dipropionate aqueous nasal spray, for ten consecutive days | Efficacy evaluation | Not mentioned | 2 |
| Bai Jie Zi, Xi Xin, Gan Sui, Yan Hu Suo, Ban Xia | |||||||
| GV14, BL20, CV17, BL12, BL13, BL23 | |||||||
|
| |||||||
|
Chen and Gu 2011 [ | 40/4–7 | 34/4–7 | San-Fu-Tie, for two-three consecutive years | Oxymetazoline hydrochloride spray and dexamethasone, withdrawal when symptomatic relief occurs | Efficacy evaluation | Not mentioned | 2 |
| Bai Jie Zi, Xi Xin, Ma Huang, Xin Yi, Sheng Jiang | |||||||
| GV14, BL13, BL43, PC6 | |||||||
|
| |||||||
| Lin et al. 2014 [ | 84/5–82 | 84/5–82 | San-Fu-Tie, four times a year (dog days are four ten-day periods in 2013), for one year | Beclometasone dipropionate aqueous nasal spray, for four weeks | Efficacy evaluation, symptom rating scale | Not mentioned | 4 |
| Bai Jie Zi, Xi Xin, Ma Huang, Gan Sui, Yan Hu Suo, Ding Xiang, Sheng Jiang | |||||||
| BL13, BL20, GV14, BL23, BL12, LI4, EX-B1, ST36, EX-HN15 | |||||||
Bai Jie Zi, Semen Sinapis Albae; Xi Xin, Herba Asari; Gan Sui, Radix Kansui; Yan Hu Suo, Rhizoma Corydalis; Sheng Jiang, Rhizome Zingiberis Recens; Ban Xia, Rhizoma Pinelliae; Ma Huang, Herba Ephedrae; Xin Yi, Flos Magnoliae; Ding Xiang, Flos Caryophylli.
BL13, Feishu; BL43, Gaohuang; EX-HN15, Bailao; CV17, Danzhong; EX-B1, Dingchuan; GV14, Dazhui; BL20, Pishu; BL12, Fengmen; BL23, Shenshu; PC6, Neiguan; LI4, Hegu; ST36, Zusanli.
AR, allergic rhinitis; cAMP, cyclic Adenosine Monophosphate; cGMP, cyclic Guanosine Monophosphate.
Asthma and acupuncture point application therapies.
| Author | Number and range of age | Intervention (herbal medicine and acupoints) and duration | Outcomes | Adverse events | Jadad score | ||
|---|---|---|---|---|---|---|---|
| Experimental | Control | Experimental | Control | ||||
| Cai 2008 [ | 40/2–12 | 40/2–12 | San-Fu-Tie, for one year | BCG polysaccharide and nucleic acid injection, twice a week, for three months | Symptom rating scale, IL-4, IFN- | No | 2 |
|
| |||||||
| Mou et al. 2009 [ | 91/18–65 | 55/18–65 | San-Fu-Tie, for three consecutive years | Oral preparation of traditional Chinese medicine, three months in one year, for three consecutive years | Efficacy evaluation, symptom rating scale | Not mentioned | 2 |
|
| |||||||
| Cai et al. 2010 [ | 60/3–14 | 60/3–14 | San-Fu-Tie, for one year | PBO, three times a year, for one year | Symptom rating scale, safety assessment | No | 4 |
|
| |||||||
| Li and Yuan 2010 [ | 30/3–8.2 | 30/3.2–8.5 | San-Fu-Tie, for one year | BCG Polysaccharide and nucleic acid injection, once every other day, for one month | Efficacy evaluation, | One patient had mild skin allergies | 4 |
|
| |||||||
| Zhang 2010 [ | 30/18–70 | 30/18–70 | San-Fu-Tie, for three consecutive years | Ketotifen, July to September each year, for three consecutive years | Efficacy evaluation | Not mentioned | 2 |
|
| |||||||
| Tao 2012 [ | 60/3–14 | 60/3–14 | San-Fu-Tie, for one year | PBO, three times a year, for one year | Symptom rating scale | No | 4 |
|
| |||||||
| Cui 2012 [ | 28/2–14 | 28/2–14 | San-Fu-Tie, for one year | Pulmicort, for one year | Symptom rating scale, IgA, IgE, IgG, IgM | Two patients had local swelling and blisters | 2 |
|
| |||||||
| Li 2012 [ | 60/3–14 | 60/3–14 | San-Fu-Tie, for one year | PBO, three times a year, for one year | Symptom rating scale, safety assessment | No | 4 |
|
| |||||||
| Zhu and Chen 2012 [ | 36/18–65 | 36/19–63 | San-Fu-Tie, for one year | Salbutamol, withdrawal when symptomatic relief occurs | Efficacy evaluation | Not mentioned | 1 |
|
| |||||||
| You et al. 2012 [ | 50/3–80 | 30/5–81 | San-Fu-Tie, for three consecutive years | Yupingfeng granules, thirty days during dog days every year, for three consecutive years | Efficacy evaluation | Not mentioned | 2 |
|
| |||||||
| Chen et al. 2013 [ | 56/3–14 | 30/2.8–14 | San-Fu-Tie, for one year | Yupingfeng granules, for thirty days during dog days, for one year | Efficacy evaluation, IgA, IgE, IgG, IgM | Not mentioned | 2 |
|
| |||||||
| Z. P. Zhang | 60/18–65 | 60/18–65 | San-Fu-Tie, for three consecutive years | Acupuncture therapy, thirty days during dog days every year, for three consecutive years | Efficacy evaluation | Not mentioned | 2 |
|
| |||||||
| Hu 2014 [ | 50/5–12 | 50/5–12 | San-Fu-Tie, for one year | Salmeterol xinafoate and fluticasone propionate powder for inhalation, for one year | Attack frequency, FEV1, FVC, PEFR | Not mentioned | 2 |
|
| |||||||
| Shi and Zhao 2014 [ | 46/3–14 | 46/2.8–14 | San-Fu-Tie, for one year | PBO, three times a year, for one year | Efficacy evaluation, FEV1, PEF, FVC, FEV1/FVC, EOS | Not mentioned | 5 |
|
| |||||||
| Chen 2014 [ | 70/4–12 | 70/4–12 | San-Fu-Tie, for one year | BCG polysaccharide and nucleic acid injection, twice a week, for three months | Symptom rating scale, IL-4, IFN- | Not mentioned | 2 |
Bai Jie Zi, Semen Sinapis Albae; Xi Xin, Herba Asari; Gan Sui, Radix Kansui; Yan Hu Suo, Rhizoma Corydalis; Sheng Jiang, Rhizome Zingiberis Recens; Ban Xia, Rhizoma Pinelliae; Ma Huang, Herba Ephedrae; Tan Xiang, Lignum Santali Albi; Rou Gui, Cortex Cinnamomi; Huang Qi, Radix Astragali; Dang Shen, Radix Codonopsis; Shan Yao, Rhizoma Dioscoreae; Gan Cao, Radix Glycyrrhizae; Bing Pian, Borneolum Syntheticum; Jiang Can, Bombyx Batryticatus; Feng Mi, Mel; Wu Zhu Yu, Fructus Evodiae; Su Zi, Fructus Perillae; She Xiang, Moschus; Fang Feng, Radix Saposhnikoviae.
BCG, Bacillus Calmette-Guérin; IL-4, interleukin-4; IFN-γ, interferon-γ; PBO, placebo; FEV1, Forced Expiratory Volume in One Second; FVC, Forced Vital Capacity; PEFR, Peak Expiratory Flow Rate; PEF, Peak Expiratory Flow; EOS, eosinophils; WBC, white blood cell; NEUT, neutrophil; LYM, lymphocyte; MONO, monocyte; RBC, red blood cell; HGB, hemoglobin; PLT, blood platelet.
BL13, Feishu; BL43, Gaohuang; EX-HN15, Bailao; CV17, Danzhong; EX-B1, Dingchuan; GV14, Dazhui; BL20, Pishu; BL12, Fengmen; BL23, Shenshu; PC6, Neiguan; LI4, Hegu; ST36, Zusanli; CV22, Tiantu; LU1, Zhongfu; BL17, Geshu; CV4, Guanyuan; BL15, Xinshu; BL11, Dazhu.
Figure 7Process of searching for and screening studies.